Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Nature Reviews. Cancer

• Publication date

  2009-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrc2615PMID 19343035
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Involvement of BH3-only proteins in hematologic malignancies.

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.

  2009cited by this paper
• Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

  2009cited by this paper
• Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors.

  2009cited by this paper
• Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737.

  2008cited by this paper
• In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas

  2008cited by this paper
• Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins.

  2008cited by this paper
• Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.

  2008cited by this paper
• The BCL-2 protein family: opposing activities that mediate cell death

  2008cited by this paper
• Diagnosing and exploiting cancer's addiction to blocks in apoptosis

  2008cited by this paper
• BCL-2 family antagonists for cancer therapy

  2008cited by this paper
• ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

  2008cited by this paper
• Translation of the Philadelphia chromosome into therapy for CML.

  2008cited by this paper
• Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.

  2008cited by this paper
• ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis*

  2008cited by this paper
• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

  2008cited by this paper
• ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo

  2008cited by this paper
• Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program

  2008cited by this paper
• Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins

  2008cited by this paper
• First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  2008cited by this paper
• Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.

  2008cited by this paper
• Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

  2008cited by this paper
• Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.

  2008cited by this paper
• BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.

  2008cited by this paper
• The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

  2008cited by this paper
• Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia

  2007cited by this paper
• Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains

  2007cited by this paper
• Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

  2007cited by this paper
• Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

  2007cited by this paper
• Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.

  2007cited by this paper
• BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations

  2007cited by this paper
• Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion.

  2007cited by this paper
• Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

  2007cited by this paper
• A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma

  2007cited by this paper
• The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts

  2007cited by this paper
• Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

  2007cited by this paper
• ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells

  2007cited by this paper
• ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737

  2007cited by this paper
• Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics

  2007cited by this paper
• The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

  2006cited by this paper
• Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

  2006cited by this paper
• Competing Interests: The authors

  2006cited by this paper
• Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic

  2006cited by this paper
• Integration of EGFR inhibitors with radiochemotherapy

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Promoting apoptosis as a strategy for cancer drug discovery

  2005cited by this paper
• Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• Promoting apoptosis as a strategy for cancer drug discovery

  2005cited by this paper
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  2005cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways

  2004cited by this paper
• Addiction to Oncogenes--the Achilles Heal of Cancer

  2002cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571*

  2002cited by this paper
• Apoptosis signaling.

  2000cited by this paper

• BCL-2 family inhibition enhances MTORC1/2 inhibition in PIK3CA mutant colorectal cancer.

  2025cites this paper
• Fatty acid synthase (FASN) inhibition cooperates with BH3 mimetic drugs to overcome resistance to mitochondrial apoptosis in pancreatic cancer

  2025cites this paper
• LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers

  2024cites this paper
• Don't fear the reaper: The role of regulated cell death in tumorigenesis and BH3-mimetics for cancer therapy.

  2024cites this paper
• Bio-mimetic strategies to re-activate apoptotic cell death for cancer treatments

  2024cites this paper
• Inhibitors Targeting the F-BOX Proteins

  2023cites this paper
• CircSLC39A8 attenuates paclitaxel resistance in ovarian cancer by regulating the miR‑185‑5p/BMF axis

  2023cites this paper
• Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology

  2023cites this paper
• Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex

  2022cites this paper
• BCL-2 protein family: attractive targets for cancer therapy

  2022cites this paper
• Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma

  2022cites this paper
• Inhibition of the TPL2-MKK1/2-ERK1/2 pathway has cytostatic effect on B-Cell Lymphoma

  2022cites this paper
• Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy

  2022cites this paper
• Review on Radiation Therapy on Cancer

  2022cites this paper
• Removal of BFL-1 sensitises some melanoma cells to killing by BH3 mimetic drugs

  2022cites this paper
• Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells

  2022cites this paper
• A brief Overview of a Fatal Disease Namely Cancer

  2021cites this paper
• CDK2-Mediated Upregulation of TNFα as a Mechanism of Selective Cytotoxicity in Acute Leukemia

  2021cites this paper
• Cell death pathways: intricate connections and disease implications

  2021cites this paper
• Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

  2021cites this paper
• Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy

  2021cites this paper
• It´s time to die: BH3 mimetics in solid tumors.

  2021cites this paper
• Co-targeting MCL-1 and ERK1/2 kinase induces mitochondrial apoptosis in rhabdomyosarcoma cells

  2021cites this paper
• The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs

  2021cites this paper
• Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics

  2021cites this paper
• Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG

  2020cites this paper
• Toward Targeting Antiapoptotic MCL-1 for Cancer Therapy

  2020cites this paper
• Cell Proliferation, Survival, Necrosis and Apoptosis

  2020cites this paper
• Differentiation of acute myeloid leukemia (AML) cells with ATRA reduces 18F-FDG uptake and increases sensitivity towards ABT-737-induced apoptosis

  2020cites this paper
• Emerging connectivity of programmed cell death pathways and its physiological implications

  2020cites this paper
• The Proliferative and Apoptotic Landscape of Basal-like Breast Cancer

  2019cites this paper
• Targeting Cancer from a Structural Biology Perspective

  2019cites this paper
• Effektive Induktion von Apoptose in den Knochenmarkzellen von Patienten mit Myelodysplastischen Syndromen (MDS) der Hochrisikogruppe oder mit sekundärer Leukämie aus MDS durch das BH3-Mimetikum ABT-737

  2019influential citation
• Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo

  2019cites this paper
• The independence of and associations among apoptosis, autophagy, and necrosis

  2018cites this paper
• Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells

  2018cites this paper
• Implication du récepteur à activité tyrosine kinase (RTK) MET sur la balance survie/apoptose et identification de nouvelles mutations de RTKs dans les cancers colorectaux métastatiques

  2018cites this paper
• The impact of phosphatases on proliferative and survival signaling in cancer

  2018cites this paper
• Cell‐based high‐throughput screen for small molecule inhibitors of Bax translocation

  2018cites this paper
• BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.

  2018cites this paper
• ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line

  2018cites this paper
• Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non-Small Cell Lung Cancer.

  2018cites this paper
• Metformin Synergizes with BCL-XL/BCL-2 Inhibitor ABT-263 to Induce Apoptosis Specifically in p53-Defective Cancer Cells

  2017cites this paper
• The role of anti-apoptotic Bcl-2 proteins for colorectal cancer development and progression

  2017cites this paper
• BCL-2: Long and winding path from discovery to therapeutic target.

  2017cites this paper
• The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice

  2017cites this paper
• The prognostic importance of TGF-β, TGF-β receptor, and fascin in childhood solid tumors

  2017cites this paper
• The anti-apoptotic protein MCL1, a novel target of lung cancer therapy

  2017cites this paper
• Function of myeloid cell leukaemia-1 and its regulative relations with hepatocellular carcinoma

  2017cites this paper
• Effect of molecular markers HIF-1α and IDH1 on the radiobiological behavior of human malignant glioma cell lines in normoxia and hypoxia

  2016cites this paper
• Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients

  2016cites this paper
• Control of Cell Survival and Apoptosis

  2016cites this paper
• Cell Death Induction by the Indirubin Derivative 7BIO and the BH3 Mimetic Drugs ABT-737 and GX15-070 in Medullary Thyroid Carcinoma Cells.

  2016cites this paper
• N'-((2-(6-bromo-2-oxo-2H-chromen-3-yl)-1H-indol-3-yl)methylene)benzohydrazide as a probable Bcl-2/Bcl-xL inhibitor with apoptotic and anti-metastatic potential.

  2016cites this paper
• Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

  2016cites this paper
• New Frontiers in Cancer Chemotherapy — Targeting Cell Death Pathways

  2016cites this paper
• A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer

  2016cites this paper
• The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells

  2016cites this paper
• Bcl-xL promotes metastasis independent of its anti-apoptotic activity

  2016cites this paper
• The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells

  2016cites this paper
• The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

  2016cites this paper
• Inhibiting cancer cell hallmark features through nuclear export inhibition

  2016cites this paper
• Taking control of the female fertile lifespan: a key role for Bcl-2 family proteins.

  2016cites this paper
• Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming

  2016cites this paper
• The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1

  2016cites this paper
• Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.

  2016cites this paper
• Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line

  2016cites this paper
• Histone modification as a drug resistance driver in brain tumors

  2016cites this paper
• BH3 mimetics: Their action and efficacy in cancer chemotherapy

  2016cites this paper
• The BCL-2 protein family, BH3-mimetics and cancer therapy

  2015cites this paper
• Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers

  2015cites this paper
• Targeting Cdc20 as a novel cancer therapeutic strategy.

  2015cites this paper
• The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil.

  2015cites this paper
• How cell death shapes cancer

  2015cites this paper
• A Time to Kill: Targeting Apoptosis in Cancer

  2015cites this paper
• microRNA-10b Is Overexpressed and Critical for Cell Survival and Proliferation in Medulloblastoma

  2015cites this paper
• Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use

  2015cites this paper
• Exploiting replicative stress to treat cancer

  2015cites this paper
• Structure-Function Analysis of the Mcl-1 Protein Identifies a Novel Senescence-regulating Domain*

  2015cites this paper
• Investigating the anti-apoptotic role of EBV in endemic Burkitt lymphona

  2015influential citation
• The Epstein-Barr virus BCL-2 homologues : interactions with cellular BCL-2 proteins and their role in apoptosis

  2015cites this paper
• Targeting apoptosis is the major battle field for killing cancers

  2015cites this paper
• Bcl‐2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupus‐Prone Mice and Dampen Interferon‐α Production

  2015cites this paper
• ABT-737 and Roscovitine induces apoptosis in a synergistic fashion in mast cells carrying the D816V KIT mutation

  2015cites this paper
• Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer

  2015cites this paper
• Mild thermotolerance induced at 40 °C protects cells against hyperthermia-induced pro-apoptotic changes in Bcl-2 family proteins

  2014cites this paper
• Melatonina y apoptosis en leucocitos humanos

  2014cites this paper
• BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737.

  2014cites this paper
• Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression

  2014cites this paper
• Functional antagonism between pro-apoptotic BIM and anti-apoptotic BCL-XL in MYC-induced lymphomagenesis

  2014cites this paper
• Molecular correlates of platinum response in human high‐grade serous ovarian cancer patient‐derived xenografts

  2014cites this paper
• Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening

  2014cites this paper
• Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts

  2014cites this paper
• APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction.

  2014influential citation
• Loss of the Proapoptotic BH3-Only Protein BCL-2 Modifying Factor Prolongs the Fertile Life Span in Female Mice1

  2014cites this paper
• Identification of cis-Acting Elements and Splicing Factors Involved in the Regulation of BIM Pre-mRNA Splicing

  2014influential citation
• Personalized Medicine and Imaging Cell and Molecular Determinants of In Vivo Ef fi cacy of the BH 3 MimeticABT-263 against PediatricAcute Lymphoblastic Leukemia Xenografts

  2014cites this paper
• DETERMINANTS OF IN VIVO EFFICACY OF THE BH 3 1 MIMETIC ABT-263 AGAINST PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA 2 XENOGRAFTS 3 4

  2014cites this paper
• BH3-Only Mimetics

  2014cites this paper
• Strategies to overcome drug resistance of receptor tyrosine kinaseaddicted cancer cells.

  2014cites this paper